Cong Claire Xu Sells $2.59K of NovaBridge Biosciences (NBP) — SEC Form 4, Sep 01, 2026

Open-Market Net Sale · SEC Form 4
−$2,593

Equity position changed by +2.0%

Reporting Owner
TXN 2026-08-31 · FILED 2026-09-01
Equity Position 307K sh 301,383 → 307,483
Equity Change +2.0% shares held after vs before
Filing Lag 1 business day within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Filing Date
2026-09-01
Report Date
2026-09-01
Accession No.
0002114309-26-000007
Accepted At
2026-09-01 22:00 UTC
Reporting Owner
Name Relationship
Cong Claire Xu CIK 0002114309
EVP
Cong Claire Xu at NovaBridge Biosciences Full insider history
Bought (12 mo) —
Sold (12 mo) $20,351
More from this insider at NovaBridge Biosciences
2026-07-07 Sell -$3,992 View
2026-06-02 Sell -$13,766 View
All filings by this insider at NovaBridge Biosciences
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Ordinary SharesF1F2F3F4 2026-08-30 M - Exercise 9,382 A — 307,483 Direct
Ordinary SharesF1F5F6F7 2026-08-31 S - Sale 3,282 D $0.79 -$2,593 304,201 Direct
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Restricted Share UnitsF3F8F9F9F1F8 2026-08-30 M - Exercise 4,079 D $0.00 4,079 Ordinary Shares Direct
Footnotes (9)
F1
The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Show more
F2
Reported securities are represented by 4,079 ADSs. Show more
F3
Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. Show more
F4
Reported securities are represented by 133,688 ADSs. Show more
F5
Reported securities are represented by 1,427 ADSs. Show more
F6
Reported sales price represents the converted sales price of the ADSs of $1.8186. Show more
F7
Reported securities are represented by 132,261 ADSs. Show more
F8
Reported securities represent ADSs. Show more
F9
On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month. Show more
5%+ Holders · 13D/G 3 filers
Other insiders at NovaBridge Biosciences
All NovaBridge Biosciences insider activity
GET /v1/forms/4/0002114309-26-000007 API docs
View Original SEC Filing